Fast Track Designation Approved by FDA for Aphton's G17DT Anti-Gastrin Immunogen for Gastric Cancer Therapy.
Business Wire › February 21, 2003
Linked as:
Extract
Fast Track Designation Approved by FDA for Aphton's G17DT Anti-Gastrin Immunogen for Gastric Cancer Therapy.
Business Editors/Health/Medical Writers
BIOWIRE2K MIAMI--(BUSINESS WIRE)--Feb. 21, 2003 Aphton Corporation (Nasdaq:APHT) - Aphton announced today that the US FDA has reviewed and granted Aphton's request for Fast Track designation for its G17DT (anti-gastr...See the full content of this document
Sponsored links
